[16] Hepatotoxicity (e.g., fatty liver, cholestasis, hepatitis, and hepatic necrosis) has been reported with tamoxifen use
Capone et al., 2020
As of April 2025, the FDA had received 520 adverse event reports related to compounded semaglutide and 480 reports concerning compounded tirzepatide
GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome type 2
Semaglutides work by curbing appetite , promoting feelings of fullness, and encouraging calorie control, making them a promising choice for those on a weight loss journey
One such potential pathway may be the regulation of certain gene expressions